Alternative splicing of cyclin D1 gene mRNA has recently been demonstrated. The novel transcript shows no splicing at the downstream exon 4 boundary and encodes a protein with an altered carboxyl-terminal domain that is a cyclin D1 variant; exon 5 is not included in the coding sequence which terminates downstream of exon 4. We here produced cells that exogenously express each form of cyclin D1 and analysed their cell cycle regulation. We found that (1) alternative splicing forms of cyclin D1 modulated entry into the cell cycle in an inverse manner; (2) both splicing forms suppressed cell growth; and (3) cells overexpressing form [a] were inhibited from entry into and completion of the S phase, although form [b]-expressing cells showed no reduction of G1-to S transition. We also found that overexpression of either cyclin D1 form upregulated Rb gene products, suggesting that this upregulation may be one of the causes of growth suppression in cyclin D1 overexpressing cells.
Introduction
There is increasing evidence that several types of human tumors display abnormalities in the cyclin D1 gene (Arnold et al., 1989; Rosenberg et al., 1991a,b; Jiang et al., 1992; Buckley et al., 1994; Motokura and Arnold, 1993; Bartkova et al., 1994; Gillet et al., 1994; Hunter and Pines, 1994; Michalides et al., 1995) . This gene, also termed prad 1 or bcl-1, is located at chromosome 11q13. Chromosomal re-arrangements at this locus in parathyroid tumors (Arnold et al., 1989; Rosenberg et al., 1991a) or certain B cell lymphomas (Rosenberg et al., 1991b) lead to increased expression of this gene. Cyclin D1 gene product has been shown to be overexpressed in a signi®cant fraction of primary human breast carcinomas (Buckley et al., 1993; Gillet et al., 1994) , esophageal carcinomas (Jiang et al., 1992) , and several other types of tumors, both in the cell lines and in the primary tumors (Motokura and Arnold, 1993; Hunter and Pines, 1994; Michalides et al., 1995; Bartkova et al., 1995) . It is well known that cyclin D1 regulates the G1-to S phase transition of the cell cycle by activating cyclin-dependent kinases (CDKs) 4 and 6, which phosphorylate the retinoblastoma protein (pRb) during G1 (Ewen et al., 1993) , leading to the activation of the transcription factor E2F (Cellappan et al., 1991; Nevins, 1992; Lam and Watson, 1993; Weinberg, 1995) . A recent study indicated that stable overexpression of cyclin D1 in rodent ®broblasts (Rat 6 embryo ®broblast) decreases the duration of the G1 phase and enhances the ®broblasts' tumorigenicity in nude mice (Jiang et al., 1993) .
In addition, overexpression of cyclin D1 in mouse NIH3T3 cells (Asano et al., 1995) and rat liver epithelial cells (Zhou et al., 1996) creates the conditions under which ampli®cation of CAD gene message that can be resistant against N-phosphonoacetyl-L-aspartate (PALA), occurs more readily. Furthermore, overexpression of cyclin D1 in transgenic mice has been shown to result in the formation of mammary tumors after a latency of longer than 1 year . By contrast, serveral overexpression studies have indicated that stable overexpression of cyclin D1 prolongs the S phase and inhibits growth in a human mammary epithelial cell line (Han et al., 1995) and that it also inhibits S phase entry in normal diploid ®broblasts (Atadja et al., 1995) . These con¯icting results on the celltransforming ability of the cyclin D1 gene might result from the dierent cell types and expression systems used in each study, and/or from dierences in the extent and timing of the overexpression of cyclin D1 protein.
Recent studies have demonstrated that cyclin D1 may be involved not only in cell-cycle regulation, as described above, but also with the mechanisms governing programmed cell death (apoptosis) (Freeman et al., 1994; Kranenburg et al., 1996) and senescence (Dulic et al., 1993; Lucibello et al., 1993) . It is clear from these investigations that cyclin D1 is involved in regulating cell proliferation, apoptosis, and senescence by more than one mechanism.
Alternative splicing of cyclin D1 gene mRNA has recently been demonstrated (Betticher et al., 1995) . The novel transcript shows no splicing at the downstream exon 4 boundary, and encodes a protein with an altered carboxyl-terminal domain that is a cyclin D1 variant without exon 5 and terminating downstream of exon 4. Betticher et al. (1995) also found that there is a polymorphism at the exon-4-intron-4 border (A or G) and that splicing between exon 4 and exon 5 is modulated by the frequency of the A/G polymorphism in the splice donor region. This ®nding raised the question of the functional dierences between these alternatively spliced forms. In this study, we attempted to answer this question by exogenously expressing both cyclin D1 forms in cultured cells and analysing their eects on cell-cycle regulation. We found that the alternatively spliced forms of cyclin D1 modulated entry into the cell cycle in an inverse manner, and that both forms suppressed cell growth. In addition, cells overexpressing form [a] were inhibited from entering and from completing the S phase. Finally we found that overexpression of cyclin D1 up-regulates pRb, which may be a cause of the growth suppression found in cells overexpressing this gene.
Results

Expression of cyclin D1 alternatively spliced mRNAs in human glioma cells
We studied the expression of cyclin D1 alternatively spliced mRNAs in human glioma cells using RT ± PCR analysis. As shown in Figure 1 , each of the three glioma cell lines studied (U251MG, T98G, U87MG) expressed both mRNAs of cyclin D1, although the ratio of form [a] to [b] mRNA diered among cell types.
We also studied the DNA polymorphism of the exon-4-intron-4 border of the cyclin D1 gene in each of the three glioma cell types and in 94 Japanese individuals using PCR ± RFLP. Betticher et al. (1995) suggested that the allele encoding A (adenine) at nucleotide position 870 is the major source of form [b] mRNA, whereas mRNA from the G (guanine) coding allele is either spliced to form [a] and [b] mRNA to an apparently equal extent or favors form [a] mRNA. Our ®nding that expression of form [b] mRNA in T98G cells (genotype AA) was higher than that of the other two cell types (genotypes AG) may support the above hypothesis. In addition, we assessed the population frequencies of A-(0.47) and G-(0.53) coding alleles in 94 Japanese individuals using PCR ± RFLP, and found that the ratio between these frequencies was almost identical to that in European individuals (Betticher et al., 1995) .
Exogenous expression of both cyclin D1 splice forms in transfectants
We transfected all three cell lines (U87MG, T98G, and U251MG cells) with cDNAs of both of the cyclin D1 forms and successfully established pooled and subclonal cell lines overexpressing each form. Our preliminary cell cycle analysis of these cell lines gave similar results, so we decided to study the U87MG lineage cells in more detail. We examined the U87MG parent cells and mock transfected cells, as well as cells transfected with either form of the cyclin D1 gene, by method of immunoblotting using a monoclonal antibody against cyclin D1 (DCS 6) and a form [a]-speci®c polyclonal antibody. We con®rmed that pooled cells (U87-a pool and U87-b pool) of transfectant expressed exogenous cyclin D1 protein, as shown in Figure 2a Figure 2 Exogenous expression of both cyclin D1 splice forms and up-regulation of pRb in the transfectants. (a) Fifty mg of total protein were run in 15% SDS ± PAGE. Immunoblotting was done with anti-cyclin D1 mouse monoclonal antibody (DCS 6). Lane 1, U87MG parent cell; Lane 2, U87-a pool, (the pooled transfected cells with cDNA for form [a] ); Lane 3, U87-b pool, (the pooled transfected cells with cDNA for form [b] . (a) shows exogenous expression of form [a] in the U87-a pool (Lane 2) and of form [b] in the U87-b pool (Lane 3). (b) Immunoblotting was done with anti-cyclin D1 polyclonal antibody that was speci®c for form [a] . Lane 1, U87MG parent cell; Lane 2, U87-a pool; Lane 3, U87-b pool. The immunoblotting shows an exogenous expression of form [a] in the U87-a pool. (c) Expression of Rb gene products (pRb), p53 in U87MG parent cell, and U87-a and -b pools. Fifty mg of total protein were run in 15% SDS ± PAGE. The results show up-regulation of pRb in the pooled transfected cells (U87-a and -b pools). p53 protein of U87MG cells was easily degraded, but that of either transfectant became stable transfectants and b-1 to b-3 for form [b] transfectants). The results of the immunoblotting (Figure 3a ) demonstrated that a-1 cells strongly expressed cyclin D1 form [a] protein, but strong expression of cyclin D1 was not detected in a-2, a-3, b-1, b-2 or b-3 subclonal cell lines. We thought that cells strongly expressing cyclin D1 as detected by immunoblotting could not be cloned, except for the a-1 cell lines. Next we assessed the subclonal cell lines immunohistochemically using the mouse monoclonal antibody against cyclin D1 (DCS 6), because this antibody reacts with both forms of cyclin D1.
Immunocytological analysis ( Figure 4A ± G) showed that the intensities of immunostaining of the transfectants were stronger than that of the mock transfected cell. The intensities of staining were a-14a-24a-3=mock transfected cells for form [a] transfectants and b-24b-1=b-34mock transfected cells for form [b] transfectants. As immunoblotting results using the cyclin D1 form [a]-speci®c polyclonal antibody were the same for the mock transfected cells and form [b] transfectants, we concluded that the immunostaining of b-1, b-2 and b-3 cells may have been due to exogenous expression of form [b] . In addition, the immunocytological staining of these cells was localized in the nucleus and nucleolus, suggesting that both cyclin D1 forms were sorted correctly. Using these cells, we studied the functional roles of both forms of cyclin D1 in cell cycle regulation by cell kinetics analysis, including Ki-67 antigen expression, BrdU labeling, and Flow cytometry.
Immunoblotting for related oncogene and suppressor gene products in cells expressing cyclin D1 [a] and [b] forms
Immunoblotting showed that overexpression of either form of cyclin D1 in pooled transfectant cells was associated with up-regulation of pRb (Figure 2c ). p53 protein of U87MG cell was easily degraded, but that of either transfectant was stable (Figure 2c ). The expression of p21/WAF1, p27/Kip1 and CDK4 did not dier between U87MG cells and transfectants (data not shown). To examine whether up-regulation of pRb and stabilization of p53 protein occurred by transfection of a PCI neo vector or by overexpression of either cyclin D1 form, mock transfected and subclonal cells were studied by immumoblotting. Stabilization of p53 protein was observed even in mock transfected cells, suggesting that this was due to transfection of the PCI neo vector. Up-regulation of pRb was observed in the subclonal cells a-1 and b-1, but not in mock transfected, a-2, a-3, b-2 or b-3 cells (Figure 3a) . In particular, a-1 cells that showed the strongest expression of cyclin D1 form [a] , also showed the strongest expression of pRb, suggesting that overexpression of cyclin D1 may induce up-regulation of pRb.
Immunoblotting for p53, p27, CDK4 and proliferating cell nuclear antigen (PCNA) in mock transfected cells and subclonal cells transfected with form [a] or form [b] did not show distinct dierences (Figure 3a) . Up-regulation of p21 was detected in a-1 cells that overexpressed form [a] (Figure 3a) . To investigate the eects of starvation and serum stimulation, we compared the expression of cyclin D1, pRb, p53, and p21 under these two conditions (Figure 3b ). The expression of cyclin D1 and p53 did not dier among mock transfected a-1 and b-2 cells, but hyperphosphorylated pRb was observed in a-1 cells under starvation conditions. After serum stimulation, all cell types expressed hyperphosphorylated pRb (Figure 3b ,
Cyclin D1 (DCS 6) p21 p21 Functional eects of alternatively spliced cyclin D1 forms on the G0 to G1 transition
To study the eect of the constitutive expression of each cyclin D1 form on the G0 to G1 transition, parent U87MG cells and transfected cells were stained with MIB-1 antibody (Key et al., 1993) against Ki-67 antigen as described in the Materials and methods. As shown in Figure 6a , the proportion of Ki-67 antigen-negative cells (G0 cells) was reduced in the U87-a pool (P50.05), whereas the proportion of G0 cells increased in the U87-b pool (P50.05). Subcloned cells (a-1 to a-3 and b-1 to b-3) and U87MG mock transfected cells were also examined. The G0 cell ratio increased in the subclonal form [b]-expressing cells (b-1, b-2 and b-3) (P50.001), but there was no statistically signi®cant dierence between the G0 cell ratios of U87MG mock transfected and form [a]-expressing cells (a-1, a-2 and a-3) ( Figure 6b ). To further investigate the functional roles of the cyclin D1 forms in the G0 to G1 transition, cells were serum starved and stained with MIB-1 antibody to detect Ki-67 antigen at the indicated time. Figure 6c shows that, during starvation, synchronization to G0 was observed time-dependently in U87MG parent cells, whereas the U87-a pool kept a lower ratio of G0 cells and the U87-b pool had a relatively high ratio of G0 cells. Pooled cells overexpressing either form of cyclin D1 may be dicult to synchronize to G0 by serum starvation. In particular, a-1 cells, among the cyclin D1 form [a]-expressing cells, continued to have a low number of G0 cells, whereas a-3 cells, which express low levels of cyclin D1 form [a] and U87MG mock transfected cells, showed time-dependent increases in the G0 ratio by serum starvation (Figure 6d ). This tendency was closely related to the extent of form [a] expression. In cyclin D1 form [b]-expressing subclonal cells, the G0 cell ratios in all three subclonal cell types were higher than that of U87MG mock transfected cells in medium containing 10% FBS (P50.001). During starvation, the G0 cell ratios of b-1 and b-2 cells increased time dependently, but b-3 cells could not be synchronized to the G0 phase (Figure 6e ). These results suggest that cyclin D1 form [a] may modulate the entrance of G0 (Figure 7b ). In cells subcloned from the pooled cells, the same results were obtained (Figure 7c,d) . We also studied the ratio of pulse labeled (30 min) BrdU incorporation after serum stimulation at the indicated time. The proportion of BrdU-positive U87MG cells and U87-b pooled cells increased 12 h after serum stimulation and then quickly fell 48 h after stimulation. By contrast, U87-a pooled cells showed a slow increase in the proportion of BrdU labeled cells, which accumulated as shown in Figure 8 . These BrdU incorporation patterns suggest that entrance to the S phase and completion of DNA synthesis may be delayed in the U87-a pooled cells. These results were con®rmed by Flow cytometry.
Fluorescence activated cell sorting (FACS) analysis after serum stimulation U87MG cells and transfectants were starved for 72 h and then growth was stimulated by adding serum to the medium as described in the Materials and methods. The cell-cycle distribution was assessed from the DNA contents by propidium iodide (PI) staining. FACS analyses of U87MG cells and U87-a and -b pooled cells con®rmed the results of BrdU pulse labeling after serum stimulation (Figures 8 and 9a ). Seventy-two hours after serum starvation, the ratio of S phase cells in the U87-a pool was higher than those of U87MG and U87-b pooled cells, but 12 h after serum stimulation, the G1 to S phase transition was inhibited. Forty-eight hours after serum stimulation, the ratio of S phase cells did not fall in the U87-a pool as was observed for the other two cell types, suggesting that the S phase was elongated in the U87-a pool (Figure 9 ). of U87MG mock transfected cells (Figure 9b ). The S phase cell ratios of b-1 and b-2 cells at 24 h were much higher than that of U87MG mock transfected cells and decreased at a slower rate than that of U87MG mock transfected cells (Figure 9b ). These results suggest that entrance to the S phase and the completion of DNA synthesis were inhibited in a-1 cells and that, in b-1 and b-2 cells, completion of the S phase was inhibited, whereas entrance to the S phase was increased. a-3 cells expressing low levels of cyclin D1 form [a] showed a similar pattern to that of U87MG mock transfected cells. The changes in the S phase cell ratio were inversely related to changes in the G1/G0 cell ratio in these cells (a-1 and b-1 and b-2 cells), suggesting that G2/M phase may not be in¯uenced by expression of exogenous cyclin D1 forms [a] and [b] .
Discussion
In this study we observed the following. First, that cell proliferation was blocked by overexpression of either splice form of cyclin D1. Second, that overexpression of form [a] increased the proportion of cells of proliferation pool (G1, S, G2/M), but overexpression of form [b] reduced the proportion of these cells. Third, that a high level of expression of cyclin D1 form [a] inhibited cells from entering and completing the S phase in the presence of serum, but in serumdepleted conditions, expression of either form of cyclin D1 accelerated cell entry into the S phase. The most important ®nding of this study is that these alternatively spliced forms of cyclin D1 may modulate the G0 to G1 phase transition in an inverse manner.
Ki-67 antigen is associated with cell proliferation and occurs throughout the cell cycle (G1, S, G2/M phases), except in resting (G0) cells (Key et al., 1993 Figure 9 FACS analysis after serum stimulation. After the cells were starved for 72 h, growth was stimulated by adding 10% serum to the medium. The cells were harvested with a Trypsin-EDTA solution at the indicated time and were stained with 50 mg/ ml of PI. The cells were analysed on an EPICS XL SYSTEM IĪ ow cytometer for DNA content. The percentage of cells in dierent phases of the cell cycle was determined using a MULTICYCLE computer program. (a) FACS analysis of U87MG and pooled cells overexpressing either form of cyclin D1 (U87-a and -b pools) after serum stimulation. The ratio of S phase cells in the U87-a pool was higher than that of S phase cells in the U87MG (U87) or U87-b pool until 12 h after serum stimulation, whereas, at 24 h, this ratio was lower in U87-a pool than in U87MG and U87-b pool. At 48 h, this ratio was higher in U87-a pool than in the U87MG and U87-b pool. (b) FACS analysis of U87MG mock transfected cells (U87 mock) and subcloned cells (a-1, a-3, b-1 and b-2) from U87-a and -b pools after serum stimulation. The ratio of S phase cells in a-1 cells that express high levels of cyclin D1 form [a] was higher than that of U87MG mock transfected cells until 10 h after serum stimulation, but the ratio of S phase cells in a-1 cells at 24 h was lower and at 32 and 48 h was higher than that of U87MG mock transfected cells. By contrast, 24 h after stimulation, the ratio of S phase cells in b-1 and b-2 was much higher than that of U87MG mock transfected cells, and these two cell types show a slow reduction in the ratio of S phase cells. The a-3 cells that express low levels of cyclin D1 form [a] show a pattern similar to that of U87MG mock transfected cells. The changes in the S phase cell ratio were inversely related to changes in the G1/G0 cell ratio 1995) have been characterized. The protein products of gas genes have been reported to have an inhibitory eect on S phase entry (Schneider et al., 1988; Ciccarelli et al., 1990; Brancolini et al., 1992) . Statin, a 57 kDa nuclear protein, has been recognized as a unique marker of quiescent G0 cells (Pellicciari et al., 1995) , although generally the functional roles of these proteins in the G0 phase have not been clari®ed. When resting, quiescent G0 cells are stimulated by serum and/or growth factors such as platelet derived growth factor (PDGF) and epidermal growth factor (EGF); products of immediate early gene families such as c-fos and c-jun become activated within a short period of time after the addition of the growth stimuli without a requirement for protein synthesis (Bravo, 1990) . These proteins interact with genomic sites containing the activating protein-1 (AP-1) sequence and modulate gene transcription (Ryder et al., 1989) . Moreover, it has been indicated that AP-1 binding activity during the G0-G1 transition is ®nely regulated and complex, involving changes both in protein expression and posttranslational modi®cation (Lallemand et al., 1997) . In addition, evidence for cross-talk between G0-G1 and G1-S transitions has also been reported (Eblen et al., 1995) . It would appear that more than one mechanism may be involved in regulating the G1 and G0 phase transitions. Our data may provide an important clue to the molecular basis of these mechanisms, and the reduction of cell proliferation may prove to be an important novel target in cancer therapy. Accordingly, further biochemical and molecular biological studies of the splice forms of cyclin D1 gene may be clinically relevant.
We also performed a cell kinetics study, using BrdU incorporation and FACS analysis to determine why cells expressing exogenous cyclin D1 forms [a] or [b] showed suppressed growth. We found that incorporation of BrdU diered in the presence and absence of serum for form [a]-overexpressing cells (a-1 and U87-a pool cells). Although, under starvation conditions, form [a]-overexpressing cells incorporated BrdU at a higher rate than they incorporated U87MG cells and U87MG mock transfected cells, after serum stimulation the situation was reversed, with U87MG parent and mock transfected cells incorporating more BrdU than form [a]-overexpressing cells. Our FACS and BrdU labeling experiments suggest that form [a]-overexpressing cells were inhibited from entering and completing S phase. Our observations are partly consistent with previous reports (Han et al., 1995; Atadja et al., 1995) . Atadja et al. (1995) also showed that normal human diploid ®broblasts that endogenously or exogenously express high levels of cyclin D1 form [a] are unable to enter S phase in response to serum stimulation. Han et al. (1995) have reported that stable overexpression of cyclin D1 in HBL-100 cells increases their doubling time and lengthens the duration of the S phase, although in serum depleted conditions, our 24 and 44 h BrdU labeling study showed that S phase entry of form [a]-overexpressing cells was not inhibited but rather increased when compared with that of U87MG cells and mock transfected cells (Figure 7) . The dierences in the culture conditions may mean that an unknown factor present in the serum is responsible for this discrepancy. Cyclin D1 form [a] associates in a ternary complex with PCNA, a 21 kDa protein (WAF-1), and cyclin dependent kinase (Xiong et al., 1992; El-Deiry et al., 1993 Waga et al., 1994) . One possible mechanism by which high levels of cyclin D1 form [a] might negatively regulate G1-S transition is through stabilization of p21 and/or by the targeting of p21 to other cyclin/CDK protein complexes. Indeed, overexpression of p21 is known to inhibit entry to the S phase and is growth suppressive (El-Deiry, 1994 ). In our immunoblotting study, form [a]-overexpressing cells (a-1) expressed higher levels of p21 protein. Therefore, it is possible that the inhibition of S phase entry of the a-1 cells may have been partly due to high expression of p21 protein. The mechanisms serving to regulate p21 expression in these p53-independent circumstances are not known, but recent accumulated evidence (Liu et al., 1996) suggests a role for the mitogen-activated protein kinase (MAPK) signaling pathway in mediating transcriptional activation of p21 in response to growth factor stimulation. Since cyclin D1 promoter activity is also stimulated by MAPK through AP-1 binding proteins (Albanese et al., 1995) , cross-regulation and activation between p21 and cyclin D1 syntheses may be suggested. For example, it has been shown that p21 induces cyclin D1 synthesis (Chen et al., 1995) and that increased cyclin D1 protein appears necessary, in concert with p21, for the induction of a proper G1 arrest as mediated by wild type p53 (Del Sal et al., 1996) . The other possible mechanism of growth suppression in our transfectants is that of the CDKs that are capable of associating with cyclin D1; a CDK4/Cyclin D1 complex is known to phosphorylate Rb protein Kato et al., 1994) , but CDK2 is also known to associate with cyclin D1 in an apparently catalytically inactive form (Xiong et al., 1992) . CDK2 is also known to associate with cyclins A and E (Walker and Maller, 1991) . Cyclin A/Cdk2 complex is probably involved in the completion of DNA synthesis (Pagano et al., 1992) and mitosis, and a role in entry to the S phase has been reported (Girard et al., 1991) . The cyclin E/CDK2 complex may play a role in G1-S phase transition (Dulic et al., 1992; Ohtsubo et al., 1995) . Thus cyclins A and E might not bind to CDK2 when a high level of cyclin D1 form [a] is associated with CDK2 in a catalytically inactive form. As a result, entry to and completion of the S phase might be impaired. The other factor may be the PCNA protein; PCNA plays an essential role in DNA replication and repair (Bravo and MacDonald-Bravo, 1987) . Thus, overexpression of both cyclin D1 forms may be involved in inhibiting the function of PCNA.
Our experiments showed up-regulation of pRb in U87-a and -b pooled cells and in a-1 and b-1 subcloned cells. The characterized target for regulation of pRb is the transcription factor E2F. During the early G1 phase, pRb binds to E2F and suppresses its activity, but as the cells progress from G1 into S phase, pRb becomes inactivated and dissociates from E2F, allowing E2F to regulate transcription (Cellappan et al., 1991; Nevins, 1992; Ewen et al., 1993; Lam and Watson, 1993; Weinberg, 1995) . Inactivation of pRb at G1-S transition is achieved through hyper-phosphorylation by the cyclin D-and Edependent kinases. More recent data (Cavanaugh et al., 1995; White et al., 1996) demonstrated that pRb can also inhibit transcription of RNA polymerase I (pol I) and III (pol III). Pol I synthesizes large ribosomal RNAs (rRNA) whereas pol III synthesizes a variety of small stable RNAs, including 5S rRNA and transfer RNA. Together pols I and III are responsible for 70 ± 80% of all nuclear transcription. Up-regulation of pRb followed by the exogenous expression of cyclin D1 may be responsible in part for the growth suppression of our transfected cells.
Cyclin D1 expression is high in early and mid G1 and decreases by about 6 ± 7-fold before onset of replication in normal human and rat ®broblasts (Pusch et al., 1996) . Since stably transfected cells may lack such cyclin D1¯uctuation throughout the cell cycle (Pusch et al., 1996) , these inhibitory eects of the cyclin D1 forms on the completion of S phase may be non-physiological.
The CDK-cyclin complexes not only have positive roles in determining when S phase or mitosis begins, but are important in preventing the initiation of an untimely cell-cycle event. For example, in ®ssion yeast, the cdc2-cdc3 complex in the G2 phase prevents more than one round of DNA replication per cell cycle (Hayles et al., 1994) . Experiments designed to examine phase speci®c expression of cyclin D1 are a promising method for studying cell cycle regulation by these proteins in the future.
During starvation conditions, BrdU incorporation in form [b]-expressing cells was higher than that in U87MG parent cells, but was lower than that in form [a]-expressing cells. This suggests that form [b] can also accelerate S phase entry under starvation conditions, although to a lesser extent than form [a] . By contrast, after serum stimulation, entry into the S phase was not inhibited in form [b]-expressing cells, but was inhibited in form [a]-expressing cells. The reason for this dierence is not clear at present. One possible explanation is that form [b] might not be associated with, or aected by, the factors that serum induces. Indeed, we observed lower p21 expression in b-2 cells after serum stimulation than in U87MG mock transfected and a-1 cells.
The molecular dierence between forms [a] and [b] is 33 amino acids of the C-terminal sequence (Betticher et al., 1995) . Form [a] possesses a PEST rich region (destruction box) that is responsible for rapid turnover (Rogers et al., 1986) , but form [b] does not contain the PEST rich sequence. This suggests that the half-life of form [b] might be longer. It is important to analyse the dierent interactions between the two forms of cyclin D1 and their associating proteins. These interactions are currently under investigtion.
The U87MG cells that were used in this study do not express p16 protein (INK 4/CDKN2) (Tenan et al., 1995) , which is a tumor suppressor protein that regulates the G1-S check point by inhibiting CDK4 activity Koh et al., 1995) . Therefore, we could not study the role of p16 protein in G0-G1 and G1-S transitions in cells with a high level of expression of cyclin D1. Further transfection studies of the p16 gene in a-1 cells are in progress.
In this report, we demonstrated that alternatively spliced forms of cyclin D1 might modulate G0-G1 transition in an inverse manner. As interactions with other gene products remain to be examined, our series on cyclin D1-overexpressing cells should be useful for studying the regulatory mechanisms of G0-G1 transition and the molecular mechanisms of cell growth and proliferation.
Materials and methods
Cell culture
The human glioma cell lines U87MG, T98G, and U251MG were cultured in Dulbecco's modi®ed essential medium (DMEM) (Nihonseiyaku, Japan) containing 10% heat inactivated fetal bovine serum (FBS) and were maintained in a 378C incubator with 5% CO 2 , 95% air.
PCR ± RFLP analysis of a polymorphism within the cyclin D1 coding sequence in glioma cells and in a cohort of Japanese subjects
To study a single base pair A/G polymorphism of the exon-4-intron-4 border of cyclin D1 coding sequence in human glioma cells and in a separate Japanese cohort, polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) analysis was performed as reported previously (Betticher et al., 1995) . Genomic DNA was isolated from cultured glioma cells and the blood of 94 Japanese individuals according to Sambrook et al. (1989) . For PCR ampli®cation, the following primers were used: forward primer, 5'-GTGAAGTTCATTTCCAATCCGC-3'; reverse primer, 5'-GGGACATCACCCTCACTTAC-3'. One mg of genomic DNA was added to a PCR mixture containing dNTP at 250 mM, 0.5 mg of each primer, 16PCR buer (Takara, Japan) and 2.5 U.Taq polymerase (Takara, Japan). Thirty PCR cycles of 1 min denaturation at 948C, 1 min annealing at 558C and 1 min elongation at 728C, were performed in an automated thermocycler. The PCR products were digested with the restriction enzyme ScrFI (Wako, Japan) and run on agarose gels consisting 3% Nusieve agarose (Takara, Japan) and 1% HS agarose (Wako, Japan) containing 0.01% ethidium bromide.
RT ± PCR analysis of alternatively spliced forms of cyclin D1 gene in human glioma cell lines U87MG, T98G and U251MG
To study whether mRNAs of cyclin D1 forms are expressed in human glioma cells, reverse transcriptase (RT) ± PCR analysis was performed using speci®c primer sets for both forms of cyclin D1: for form [a], reverse primer, 5'-CAAGGAGAATGAAGCTTTCCCTT-3' (3' UTR beyond exon 5); and for form [b] , reverse primer, 5'-GGGACAT-CACCCTCACTTAC-3' (intron 4). The foward primer, 5'-CCTACTTCAAATGTGTGCAGAAG-3' (exon 1), was common to both forms. mRNA isolation from culture cells and RT ± PCR conditions are described below. The resultant PCR products were run on 1.5% agarose gel containing 0.01% ethidium bromide. A RT ± PCR control ampli®er set for human glyceraldehyde 3-phosphate dehydrogenase (G3PDH) (Clontech, CA) was used as a positive control for cDNA synthesis and PCR ampli®cation.
Expression vector construction and transfection
The 1.3 kb human cyclin D1 cDNA (form [a] ) containing the entire coding sequence was kindly provided by Dr Y Xiong (Xiong et al., 1992) and was inserted at the EcoRI site of pCI neo Mammalian Expression Vector (Promega, WI). The cDNA of the alternatively spliced form [b] of cyclin D1 (Betticher et al., 1995) was cloned by RT ± PCR for the mRNA of T98G cells because these cells expressed the highest levels of form [b] mRNA among the human glioma cell lines examined (Figure 1) . Brie¯y, total RNA was prepared from T98G cells, using Isogen solution according to the manufacturer's protocol (Wako, Japan). T98G cells were resolved in Isogen solution and an equal volume of chloroform was added. After centrifugation for 5 min at 18 000 g, the aqueous phase was precipitated with isopropanol. Poly(A) + RNA was puri®ed, using oligo-dTlatex (Oligo-dT 30 super, Takara, Japan) beads. Using 1 mg of poly(A) + RNA as template, cDNA was then produced with reverse transcriptase (Promega, WI) and random priming. The resultant cDNA was ampli®ed by 40 PCR cycles of 45 s at 958C, 45 s at 558C, and 45 s at 728C, using a GeneAmp RNA system (Perkin Elmer, CT) according to manufacturer's protocols. The primer sets used for ampli®cation of cyclin D1 consisted of forward primer 5'-GCGAATTCATGAACACCAGCTCCTGTG-3', and reverse primer 5'-GCGAATTCCAACCTTGTCACCCTTG-GGG-3'. The ampli®ed DNA fragment was subcloned by TA cloning vector (Invitrogen, WI) and sequenced by the chain termination method (Sanger et al., 1977) . The 0.9 kbp cyclin D1 form [b] cDNA was insertd at the EcoRI site of pCI neo vector.
cDNA of cyclin D1 forms ([a] and [b] ) were also inserted at the EcoRI site of mammalian expression vector pZeoSV2 (+) (Invitrogen, WI) containing a gene that confers resistance to the antibiotic Zeocin (Invitrogen, WI).
Transfection of cyclin D1 expression vector was performed using lipofectoamine (Gibco BRL, MD) as follows. Two micrograms of cyclin D1 expression vector, 20 ml of lipofectoamine and 200 ml of opti-MEM (Gibco BRL, MD) were mixed and left for 30 min at room temperature. One ml of opti-MEM was added to the mixture. The liquid was overlaid to human glioma cells that were washed three times with opti-MEM, and the cells were incubated at 378C for 5 h. The transfected cells were then cultured for 2 weeks in the DMEM containing 10% FBS containing 1 mg/ml (active) of geneticine (Wako, Japan). The pooled transfected cells were subcloned as follows. One hundred of the geneticine-resistant pooled cells were plated in the 10 cm culture dish (Iwaki, Japan) and cultured for 7 days. The colonies were marked with a color pen under microscopy and were detached using a small piece (363 mm) of soft paper soaked in Trypsin-EDTA solution (Gibco BRL, MD). The cloned cells were cultured in a 24-well culture dish (Nunc, IL) and expanded for further analysis. U87MG cells were also transfected with the pCIneo vector alone, as described above and the pooled transfectants (U87 mock) was used for the control study.
To examine whether form [b] competes in function with form [a] in the G0-to G1 transition, a-1 cells that expressed high levels of form [a] were double-transfected with pZeoSV2 (+), or with pZeoSV2 (+) that was inserted form [b] cDNA (pBF). These pooled transfectants were cultured in DMEM containing 10% FBS and 250 mg/ml Zeocin for 2 weeks. Each Zeocin resistant pooled transfected cell was then starved for 72 h as described below in`Starvation experiments'. The cells were stained with MIB-1 antibody as described iǹ Immunocytochemistry'.
Growth curves
One thousand cells were plated in each well of the 24 well culture dish (Nunc, IL) in the presence of 0.1%, 1%, 3%, or 10% FBS. Every 2 days, cells were detached with a Trypsin-EDTA solution and counted using a Coulter cell counter. The growth of U87MG mock transfected cells (U87 mock) and subcloned cells (a-1, a-2, a-3, b-1, b-2 and b-3) from the U87-a and -b pools was also studied in the presence of 10% FBS.
Flow cytometery
One million cells were plated in 10 cm culture dish (Iwaki, Japan) and cultured in DMEM containing 10% FBS for 3 days. The medium was then replaced with DMEM containing 0.1% FBS and, after 48 h, again replaced with medium containing 10% FBS. The cells were harvested at the indicated time before and after the addition of 10% serum. The cells were collected and washed twice with phosphate buered saline (PBS). Cell pellets were resuspended in 1 ml PBS, ®xed in 10 ml of 70% ethanol, and stored at 48C. On the day of analysis, cells were collected by centrifugation and the pellets were resuspended in cell densities of 1610 6 /ml with PBS and treated with 1 mg/ml of RNAse A (Sigma, MO) for 60 min at 378C. The cell suspension was incubated with 50 mg/ml of propidium iodide (PI) (Sigma, MO) in the dark at room temperature for 30 min. The suspension was ®ltered through a 60 mm mesh ®lter and analysed on an EPICS XL SYSTEM II¯ow cytometer (Coulter, FL) for DNA content. The percentage of cells in dierent phases of the cell cycle was determined using a MULTICYCLE computer program (Phoenix Flow Systems, CA).
Starvation experiments
Five thousand cells were cultured on triplicate Labtec chamber slides (Nunc, IL) for 48 h in DMEM containing 10% FBS, after which the medium was replaced with DMEM containing 0.1% FBS. At the indicated times, cells were ®xed with 70% ethanol, and stained with an antibody against Ki-67 (MIB-1) (Immunoteck, France).
The cells were also labeled with 10 mM 5'-bromodeoxyuridine (BrdU) for 24 h or 44 h under starvation conditions and were stained with anti-BrdU mouse monoclonal antibody (Br-3) (CALTAG, CA) as described in`Immunocytochemistry'. All experiments were performed in triplicate, and over 1000 cells were counted under light microscopy in each.
Growth stimulation experiments
Five thousand cells were plated on Labtec chamber slides in DMEM medium containing 10% FBS and grown for 72 h. The medium was then replaced with DMEM containing 0.1% FBS and the cells were maintained for 48 h under starvation conditions. The medium was again replaced with DMEM containing 10% FBS. The cells were then ®xed with 70% ethanol at the indicated time after growth stimulation by adding serum. The cells were pulselabeled with 10 mM BrdU for 30 min at the indicated time after growth stimulation. The cells were stained with antiBrdU antibody as described below in`Immunocytochemistry'. All experiments were performed in triplicate, and over 1000 cells were counted under light microscopy in each.
Immunocytochemistry
Cell cultures grown on Labtec chamber slides (Nunc, IL) were washed with 50 mM Tris-HCl, pH 7.6, and 150 mM NaCl (TBS), and ®xed with 70% ethanol for 10 min. The intrinsic peroxidase activity was quenched by 0.3% H 2 O 2 in methanol for 20 min. Immunostaining was then performed with the anti-human Ki-67 monoclonal antibody (MIB-1) (diluted 1 : 500 with TBS) for 1 h at room temperature. After washing three times with TBS, a 1 : 500 diluted solution of biotinylated anti-mouse IgG (Dako, Denmark) in TBS was reacted for 1 h at room temperature and followed by avidin-biotin peroxidase complex (Dako, Denmark) for 30 min. After washing three times as well, the peroxidase reaction was performed with 3-3'-diaminobenzidine tetrachloride (Wako, Japan) in the presence of 0.03% H 2 O 2 . Nuclear staining was done with hematoxylin solution. For BrdU staining, before anti-BrdU mouse monoclonal antibody (Br-3) (diluted 1 : 3000 with TBS) was applied to the glass slides, DNA denaturation with 4N HCl was performed for 30 min, and 0.05% Tween 20 (Sigma, MO) was added in all solutions for washing and antibody dilution. For cyclin D1 staining, anti-cyclin D1 mouse monoclonal antibody (DCS 6) (diluted 1 : 100 with TBS) (Progen, Heidelberg, Germany) was used. IgG2a (Gamma-2a-Chains), mouse [Negative Cotnrol] (Dako, Denmark) was used as a control.
Immunoblotting
Protein extraction and immunoblotting analysis were performed as follows. Exponentially growing cells were collected with a cell scraper and washed three times with ice-cold TBS. The cell pellets were re-suspended in lysis buer (20 mM Tris-HCl, 2 mM EDTA, NP-40 and 1 mM PMSF). This suspension was sonicated three times with a Soni®er Cell Disruptor. Protein concentrations were determined by the method of Lowry et al. (1951) . For immunoblotting, 50 mg of protein in the total cell lysates were subjected to 10% or 15% SDS ± PAGE (Laemmli, 1970) . The proteins were transferred to the nitrocellulose membrane according to Towbin et al. (1979) . Membranes were blocked with 1% free fat milk in TBS for 60 min at room temperature. The membranes were then incubated with a 1 : 100 dilution of anti-cyclin D1 monoclonal antibody (DCS-6) or anti-cyclin D1 form [a]-speci®c polyclonal antibody (Upstate Biotechnology incorporated, NY) overnight at room temperature. This polyclonal antibody was produced by immunization with a synthetic peptide corresponding to the 11 C-terminal amino acids (residues 285 ± 295) of human cyclin D1 form [a] . Since the C-terminal amino acid sequence of form [b] is dierent from that of form [a], it does not recognize form [b] . As the monoclonal antibody DCS-6 was generated by polyethylene glycol-mediated fusion of NS-2 myeloma cells with splenocytes of a Balb/c mouse immunized with the fulllength recombinant human cyclin D1 protein (Bartokova et al., 1994) , it may react both forms of cyclin D1. Anti-Rb (Ab-5, mouse monoclonal, 1 : 50), p21/WAF-1 (Ab-1, mouse monoclonal, 1 : 50), CDK4 (Ab-1, rabbit polyclonal, 1 : 200) and p27/Kip1 (Ab-1, rabbit polyclonal, 1 : 200) were obtained from Calbiochem, MA, anti-p53 (DO-7, mouse monoclonal, 1 : 100) from Dako, Denmark, and PCNA (mouse monoclonal, 1 : 100) from Immunoteck, France. These antibodies were also diluted with TBS and incubated overnight. After washing with washing buer (TBS containing 0.05% Tween 20), the membranes were reacted with a 1 : 2000 dilution of alkaline phosphataselinked anti-mouse IgG or anti-rabbit IgG (Dako, Denmark) for 1 h. The membranes were then washed three times with washing buer and immune detection was performed using the mixture of nitroblue tetrazolium (NBT) (Wako, Japan) and isopropyl-b-D-thiogalactopyranoside (BCIP) (Wako, Japan) in 100 mM Tris HCl, pH 9.0, 150 mM NaCl, and 5 mM MgCl 2 .
